PSMA and FDG PET scans before 177Lu-PSMA therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread and is getting worse despite hormone therapy and chemotherapy.
- You have already been treated with a taxane chemotherapy (like docetaxel) and at least one anti-androgen drug (like enzalutamide).
- You are in good general health (able to be up and about most of the day).
- You are able to lie still for about 30 to 60 minutes for a PET scan.
- You are on a social health plan (like Medicare or equivalent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
This trial tests whether a special PET scan (called PSMA, which pictures prostate cancer cells) can help doctors better find any remaining or spread of prostate cancer when your PSA level is rising again. It's for people who are planning radiation therapy, and the goal is to see if the scan changes the treatment plan.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial is testing whether a special PET scan before treatment can predict what dose of a radioactive drug will go to your cancer, helping doctors plan and personalize your care. The drug used is called 177Lu-PSMA-617, which targets prostate cancer cells that have a specific marker (PSMA).
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.